Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation Review
| Authors: | Sermer, D.; Elavalakanar, P.; Abramson, J. S.; Palomba, M. L.; Salles, G.; Arnason, J. |
| Review Title: | Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation |
| Abstract: | CD19 is nearly ubiquitously expressed on B-lymphocytes and in B-cell malignancies. Although CD19-directed CAR T cells have greatly improved outcomes in B-cell malignancies, there are significant limitations with this therapy. CD19 can also be effectively targeted by other drug classes, such as monoclonal antibodies, antibody-drug conjugates, and bispecific T cell engagers or antibodies. However, the optimal patient selection and sequencing of these novel therapies has not yet been established. In this review, we discuss the utilization of CD19 as a target for the treatment of DLBCL, focusing on tafasitamab, loncastuximab tesirine, and blinatumomab. We provide a comprehensive review of the pivotal clinical trials, discussing the strength and limitations of the data for each agent. We explore the emerging evidence that CD19 expression is retained following exposure to these agents and that patients can be successfully re-challenged with anti-CD19 therapies of a different drug class upon disease relapse post-CAR T cells. Finally, we discuss how these drugs potentially fit into the most current treatment paradigm for DLBCL. © 2022 The Authors |
| Keywords: | mitogen activated protein kinase; protein kinase b; cancer survival; overall survival; lenalidomide; drug tolerability; neutropenia; review; ascites; diarrhea; hypertension; hypophosphatemia; monotherapy; nonhuman; drug targeting; gemcitabine; rituximab; neurotoxicity; anorexia; antigen expression; lymphocyte proliferation; t lymphocyte; t-lymphocytes; metabolism; drug eruption; infection; mantle cell lymphoma; neoplasm recurrence, local; anemia; thrombocytopenia; hypercalcemia; waldenstroem macroglobulinemia; immunoglobulin enhancer binding protein; antineoplastic activity; data base; acute lymphoblastic leukemia; b lymphocyte; b-lymphocytes; abdominal pain; asthenia; coughing; drug fever; febrile neutropenia; hyperglycemia; pneumonia; acute kidney failure; hypokalemia; hyponatremia; lymphocyte differentiation; nonhodgkin lymphoma; receptors, antigen, t-cell; tumor recurrence; mammalian target of rapamycin; brain disease; peripheral edema; chimeric antigen receptor; pleura effusion; seizure; lymphoma, large b-cell, diffuse; aphasia; abnormally high substrate concentration in blood; oxaliplatin; chronic lymphatic leukemia; pericardial effusion; neurologic disease; follicular lymphoma; marginal zone lymphoma; cytopenia; adoptive immunotherapy; immunotherapy, adoptive; cd19 antigen; lymphocyte antigen receptor; antigens, cd19; diffuse large b-cell lymphoma; etiology; randomized controlled trial (topic); adverse event; cytokine release syndrome; photosensitivity disorder; diffuse large b cell lymphoma; cd19; mapk signaling; blinatumomab; ibrutinib; humans; human; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; lymphocytic lymphoma; chimeric antigen receptor t-cell immunotherapy; chimeric antigen receptor t cell therapy; treatment response time; tafasitamab; akt/mtor signaling; nf kb signaling; loncastuximab tesirine |
| Journal Title: | Blood Reviews |
| Volume: | 57 |
| ISSN: | 0268-960X |
| Publisher: | Churchill Livingstone |
| Date Published: | 2023-01-01 |
| Start Page: | 101002 |
| Language: | English |
| DOI: | 10.1016/j.blre.2022.101002 |
| PUBMED: | 35989138 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 March 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work